Addressing serious fungal infections through a pipeline of innovative therapeutics
Cidara (NASDAQ: CDTX) is focusing on the discovery, development, and commercialization of therapeutics to treat serious fungal infections. The company’s pipeline is based on two core technologies: 1) “Cloudbreak”, an innovative immunotherapy approach to recruit the immune system to the sites of serious fungal infections, and 2) CD101, a next-generation echinocandin drug that enables both IV and topical formulations. Cidara was named to FierceBiotech's "Fierce 15" in 2014, and the company priced its IPO in 2015.
